Chifeng Gold (06693) obtains the controlling shareholder Li Jinyang's release of the pledge of 34 million shares of the company.
Chifeng Gold (06693) announced that on December 29, 2025, the company received a notice from its controlling shareholder, Ms. Li Jinyang, informing them that she had completed the procedures to release part of the company's pledged shares. On December 25, 2024, Ms. Li Jinyang obtained a "Securities Pledge Registration Certificate" from China Securities Depository and Clearing Corporation Limited, pledging her 34 million shares of the company to Tibet Trust Co., Ltd. for financing. Recently, Ms. Li Jinyang completed the procedures to release the above-mentioned pledged shares and obtained a "Notice of Release of Securities Pledge Registration" on December 29, 2025.
Chifeng Gold (06693) announced that on December 29, 2025, the company received a notification from its controlling shareholder, Ms. Li Jinyang, that she had completed the procedures to release part of the company's shares that were pledged. On December 25, 2024, Ms. Li Jinyang obtained a "Securities Pledge Registration Certificate" issued by China Securities Depository and Clearing Corporation Limited, pledging 34 million shares of the company to Tibet Trust Co., Ltd. for financing. Recently, Ms. Li Jinyang completed the procedures to release the pledged shares mentioned above, and obtained a "Notice of Release of Securities Pledge Registration" on December 29, 2025.
Related Articles
The merger of CHUANGLIAN HOLD (02371) will take effect on January 2, 2026.
CSPC PHARMA (01093): Potent aldosterone synthase inhibitor (SYH2072 tablet) granted clinical trial approval in China.
STERLING GP (01825) plans to offer a premium of approximately 7.5% to sell up to 69.12 million shares. The net proceeds are expected to be approximately 67.7 million Hong Kong dollars.
The merger of CHUANGLIAN HOLD (02371) will take effect on January 2, 2026.
CSPC PHARMA (01093): Potent aldosterone synthase inhibitor (SYH2072 tablet) granted clinical trial approval in China.
STERLING GP (01825) plans to offer a premium of approximately 7.5% to sell up to 69.12 million shares. The net proceeds are expected to be approximately 67.7 million Hong Kong dollars.
